Olema Pharmaceuticals Inc (OLMA)

May 21, 2026, 5:00 PM EDT - 3 days ago

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

May 19, 2026, 4:30 PM EDT - 5 days ago

Olema Oncology to Participate in Upcoming Investor Conferences

2026-05-14T09:55:47.000Z - 10 days ago

Citi opens ‘upside 90-day catalyst watch’ on Olema Oncology

2026-05-13T11:16:30.000Z - 11 days ago

Olema Oncology price target lowered to $35 from $38 at Guggenheim

PFE

May 12, 2026, 7:00 AM EDT - 12 days ago

Olema Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 12 days ago

Olema Pharmaceuticals Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 20 days ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 29, 2026, 4:01 PM EDT - 25 days ago

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Apr 29, 2026, 8:00 AM EDT - 25 days ago

Olema Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 25 days ago

Olema Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 4:01 PM EDT - 4 weeks ago

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

2026-03-26T20:15:33.000Z - 2 months ago

Olema Oncology initiated with a Peer Perform at Wolfe Research

2026-03-19T09:20:27.000Z - 2 months ago

Olema Oncology assumed with a Buy at Jefferies

2026-03-18T11:28:42.000Z - 2 months ago

Olema Oncology price target raised to $58 from $55 at JPMorgan

2026-03-18T10:35:43.000Z - 2 months ago

Olema Oncology price target lowered to $27 from $38 at Goldman Sachs

2026-03-17T11:02:53.000Z - 2 months ago

Olema Oncology price target lowered to $38 from $40 at Guggenheim

AZN

2026-03-17T09:50:12.000Z - 2 months ago

Olema Oncology price target raised to $62 from $60 at Citi

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Olema Pharmaceuticals Annual report: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Olema Pharmaceuticals Earnings release: Q4 2025

Mar 9, 2026, 1:57 PM EDT - 2 months ago

Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA

Mar 3, 2026, 2:30 PM EST - 2 months ago

Olema Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 8:00 AM EST - 3 months ago

Olema Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 1:00 PM EST - 3 months ago

Olema Pharmaceuticals Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 11, 2026, 10:00 AM EST - 3 months ago

Olema Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-10T21:23:37.000Z - 3 months ago

Olema Oncology initiated with a Buy at Stifel

Jan 30, 2026, 4:01 PM EST - 4 months ago

Olema Oncology Announces Departure of Chief Operating and Financial Officer

Jan 22, 2026, 10:26 AM EST - 4 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 13, 2026, 2:15 PM EST - 4 months ago

Olema Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 7:00 AM EST - 4 months ago

Olema Pharmaceuticals Slides: Corporate presentation

2026-01-07T13:32:10.000Z - 4 months ago

Olema Oncology initiated with a Buy at UBS

2026-01-07T13:29:38.000Z - 4 months ago

Olema Oncology initiated with a Buy at UBS

2026-01-07T10:20:24.000Z - 4 months ago

Olema Oncology initiated with an Overweight at Piper Sandler

Jan 5, 2026, 7:00 AM EST - 4 months ago

Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 4:40 PM EST - 6 months ago

Olema Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 21, 2025, 4:30 PM EST - 6 months ago

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

Nov 20, 2025, 4:01 PM EST - 6 months ago

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Nov 19, 2025, 4:00 AM EST - 6 months ago

Olema Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 4:51 PM EST - 6 months ago

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 18, 2025, 4:21 PM EST - 6 months ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN JNJ LLY MDT MRK NVO PFE

Nov 18, 2025, 10:21 AM EST - 6 months ago

OLMA stock: could today's 197% surge be just the beginning?

Nov 12, 2025, 8:00 AM EST - 6 months ago

Olema Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 4:00 PM EST - 6 months ago

Olema Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 4:00 PM EST - 6 months ago

Olema Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 10:30 AM EST - 6 months ago

Olema Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 7:00 AM EST - 6 months ago

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Oct 30, 2025, 4:30 PM EDT - 7 months ago

Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

Oct 30, 2025, 3:25 PM EDT - 7 months ago

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Oct 19, 2025, 6:00 PM EDT - 7 months ago

Olema Pharmaceuticals Slides: Corporate Presentation

Oct 18, 2025, 3:00 AM EDT - 7 months ago

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Sep 9, 2025, 9:30 AM EDT - 9 months ago

Olema Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 10:00 AM EDT - 9 months ago

Olema Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 11:30 AM EDT - 9 months ago

Olema Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:45 PM EDT - 9 months ago

Olema Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 4:00 PM EDT - 9 months ago

Olema Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 7:00 AM EDT - 9 months ago

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

PFE

Aug 11, 2025, 4:01 PM EDT - 10 months ago

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

Aug 11, 2025, 4:00 PM EDT - 10 months ago

Olema Pharmaceuticals Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 10 months ago

Olema Pharmaceuticals Earnings release: Q2 2025

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Olema Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 11:40 AM EDT - 1 year ago

Olema Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Olema Pharmaceuticals Slides: Corporate Presentation

May 28, 2025, 7:00 AM EDT - 1 year ago

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 27, 2025, 5:00 PM EDT - 1 year ago

Olema Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 20, 2025, 1:30 PM EDT - 1 year ago

Olema Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 4:01 PM EDT - 1 year ago

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

May 13, 2025, 4:00 PM EDT - 1 year ago

Olema Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Olema Pharmaceuticals Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Olema Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Olema Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Mar 25, 2025, 4:31 PM EDT - 1 year ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Mar 18, 2025, 4:01 PM EDT - 1 year ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Mar 18, 2025, 4:00 PM EDT - 1 year ago

Olema Pharmaceuticals Annual report: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

Olema Pharmaceuticals Earnings release: Q4 2024

Mar 5, 2025, 10:30 AM EST - 1 year ago

Olema Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 18, 2025, 7:00 AM EST - 1 year ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Feb 12, 2025, 9:20 AM EST - 1 year ago

Olema Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Olema Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 7:00 AM EST - 1 year ago

Olema Pharmaceuticals Registration statement: Registration Filing

Jan 3, 2025, 7:00 AM EST - 1 year ago

Olema Pharmaceuticals Registration statement: Registration Filing

Jan 2, 2025, 7:00 AM EST - 1 year ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 8:00 AM EST - 1 year ago

Olema Pharmaceuticals Transcript: Status Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

Olema Pharmaceuticals Press release: Status Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

Olema Pharmaceuticals Slides: Status Update

Dec 10, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Dec 9, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Dec 3, 2024, 3:15 PM EST - 1 year ago

Olema Pharmaceuticals Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 2:10 PM EST - 1 year ago

Olema Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 5:30 PM EST - 1 year ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Nov 20, 2024, 8:30 AM EST - 1 year ago

Olema Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 7:00 AM EST - 1 year ago

Olema Pharmaceuticals Earnings release: Q3 2024

Nov 19, 2024, 7:00 AM EST - 1 year ago

Olema Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 4, 2024, 7:45 AM EDT - 1 year ago

Olema Pharmaceuticals Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Olema Pharmaceuticals Quarterly report: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Olema Pharmaceuticals Earnings release: Q2 2024

May 28, 2024, 7:03 AM EDT - 2 years ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 22, 2024, 7:00 AM EDT - 2 years ago

Olema Pharmaceuticals Slides: Corporate Presentation

May 15, 2024, 8:00 AM EDT - 2 years ago

Olema Pharmaceuticals Transcript: Study Update

May 15, 2024, 8:00 AM EDT - 2 years ago

Olema Pharmaceuticals Press release: Study Update

May 15, 2024, 8:00 AM EDT - 2 years ago

Olema Pharmaceuticals Slides: Study Update

May 15, 2024, 7:01 AM EDT - 2 years ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 8, 2024, 4:02 PM EDT - 2 years ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:02 AM EDT - 2 years ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 8, 2024, 7:00 AM EDT - 2 years ago

Olema Pharmaceuticals Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Olema Pharmaceuticals Earnings release: Q1 2024

May 1, 2024, 7:02 AM EDT - 2 years ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Olema Pharmaceuticals Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Olema Pharmaceuticals Proxy statement: Proxy Filing

Apr 8, 2024, 4:30 PM EDT - 2 years ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Mar 11, 2024, 4:03 PM EDT - 2 years ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Olema Pharmaceuticals Earnings release: Q4 2023

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Olema Pharmaceuticals Annual report: Q4 2023

Mar 6, 2024, 7:03 AM EST - 2 years ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Jan 31, 2024, 7:00 AM EST - 2 years ago

Olema Pharmaceuticals Registration statement: Registration Filing

Jan 8, 2024, 8:12 AM EST - 2 years ago

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Jan 2, 2024, 4:01 PM EST - 2 years ago

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 12:27 PM EST - 2 years ago

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Nov 29, 2023, 1:20 PM EST - 2 years ago

Olema Pharmaceuticals Transcript: The 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 5:10 PM EST - 2 years ago

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Nov 7, 2023, 4:02 PM EST - 2 years ago

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:00 AM EST - 2 years ago

Olema Pharmaceuticals Quarterly report: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Olema Pharmaceuticals Earnings release: Q3 2023

Nov 1, 2023, 4:27 PM EDT - 2 years ago

Olema Oncology to Participate in Upcoming Investor Conferences in November